Sign In

Jeffrey Klunzinger

Awaken Capital Founder & General Partner | Investing in Tech-Enabled Platforms

Jeff Klunzinger is a seasoned professional in the investment industry with over two decades of experience across various sectors and asset classes.

He is the Founder and General Partner of Awaken Capital and has a unique perspective on private and public markets.

Previously, Jeff co-founded OS Fund and has been instrumental in successful investments in companies like Ginkgo Bioworks, Atomwise, and Pivot Bio.

Jeff's leadership qualities were acknowledged at SynBioBeta's Annual Engineering Biology Awards in 2018 for his contributions to Synthetic Biology.

Before his ventures in investment firms, he was part of West Family Investments and started his career at Ernst & Young focusing on estate and investment strategies.

Jeff holds a degree from Michigan State University and is a non-practicing Certified Public Accountant.

Apart from his professional pursuits, Jeff enjoys activities like tennis, golf, SCUBA diving, and traveling.

Highlights

Aug 25 · linkedin

Congratulations to NuMat Technologies and Sumitomo Chemical on their partnership announcement focused on sustainable chemical separation technologies that can efficiently and dramatically reduce the carbon emissions and carbon footprint required to produce critical chemicals used in key sectors of the global economy.

This partnership is just a taste of the capabilities of the programmable chemistry platform at NuMat Technologies. This is ESG in action that can truly make a difference!

https://lnkd.in/eMTcqMqf

#esginvesting #sustainability #programmablechemistry #innovation

May 11 · linkedin

Congratulations to the Ginkgo Bioworks, Inc. team on their $17.5 Billion merger with Soaring Eagle Acquisition!

It is rare you see such a strong founding team stick together and continue to add value throughout the life of the company – a special congrats to Jason Kelly, Reshma Shetty, Austin Che, Barry Canton and Tom Knight. We at OS Fund are proud to part of the incredible journey since 2014 and firmly believe the best is ahead!

This transaction allows Ginkgo to further strengthen its leadership in programmable biology which can impact numerous industries including Consumer/Tech (fragrances, cannabinoids, insect repellent, high tech electronics), Industrials/Environmental (commodities/specialty chemicals, textiles, environment), Agriculture (fertilizers & crop enhancement, crop protection, animal feed), Food/Nutrition (animal-free proteins, flavors / sweeteners, nutrition, brewing/baking), Pharma/Biotech (mRNA, Microbiome therapeutics, biologics/gene therapy, antibiotics/APIs, CV19 vaccines and therapeutics).

#syntheticbiology #synbio #venturecapital #spac #esginvesting

Jeffrey Klunzinger
Add to my network

Location

Greater Chicago Area